JPMorgan Chase & Co. set a €110.00 ($123.60) price target on Merck KGaA (FRA:MRK) in a research report report published on Wednesday, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.
A number of other equities analysts have also recently commented on MRK. Goldman Sachs Group set a €94.00 ($105.62) price target on Merck KGaA and gave the stock a sell rating in a research note on Tuesday, July 28th. DZ Bank reissued a buy rating on shares of Merck KGaA in a research note on Wednesday, July 22nd. Nord/LB set a €110.00 ($123.60) target price on Merck KGaA and gave the company a neutral rating in a research note on Friday, May 15th. Barclays set a €90.00 ($101.12) target price on Merck KGaA and gave the company a sell rating in a research note on Wednesday, June 3rd. Finally, Credit Suisse Group set a €125.00 ($140.45) target price on Merck KGaA and gave the company a buy rating in a research note on Wednesday, July 22nd. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. Merck KGaA currently has an average rating of Hold and an average price target of €108.64 ($122.07).
Shares of Merck KGaA stock opened at €108.05 ($121.40) on Wednesday. The business’s 50 day simple moving average is €107.71 and its two-hundred day simple moving average is €106.94. Merck KGaA has a one year low of €76.60 ($86.07) and a one year high of €115.00 ($129.21).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: Terms to Better Understand Call Options
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.